B

BridgeBio Pharma
D

BBIO

23.430
USD
0.17
(0.73%)
Market Closed
Volume
75,345
EPS
-3
Div Yield
-
P/E
-10
Market Cap
4,428,031,061
OverviewSignalsIdeasNews
Related Instruments
    A
    AACG
    -0.03000
    (-2.94%)
    0.99000 USD
    ABBV
    ABBV
    -4.630
    (-2.73%)
    176.95 USD
    A
    ABCL
    -0.11000
    (-3.99%)
    2.65000 USD
    ABEV
    ABEV
    0.01000
    (0.45%)
    2.21000 USD
    A
    ACOR
    -0.26810
    (-30.48%)
    0.61160 USD
    A
    ALB
    1.450
    (1.42%)
    103.570 USD
    A
    ALLO
    -0.19000
    (-7.71%)
    2.27500 USD
    A
    ALT
    -0.85500
    (-10.11%)
    7.60000 USD
    A
    AMRN
    -0.01500
    (-2.88%)
    0.50510 USD
    A
    AMRX
    -0.53500
    (-5.94%)
    8.47500 USD
    A
    ANAB
    -1.150
    (-5.69%)
    19.060 USD
    A
    ASB
    -0.090
    (-0.34%)
    26.590 USD
    A
    AXDX
    -0.01000
    (-0.54%)
    1.85000 USD
    A
    AXSM
    -4.300
    (-4.41%)
    93.150 USD
    B
    BCRX
    -0.41500
    (-5.57%)
    7.03500 USD
    More
News

Title: BridgeBio Pharma

Sector: Healthcare
Industry: Biotechnology
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, acoramidis (AG10), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.